REVA to Present at Citi 2012 Global Healthcare and ASX Small to Mid Caps Conferences

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and CEO, Robert Stockman, is scheduled to present at the Citi 2012 Global Healthcare Conference at 9:00 a.m. US EST on Monday, February 27, 2012. The conference is being held February 27 through 29, 2012 at The Waldorf Astoria Hotel in New York.

Mr. Stockman will also present at the ASX Small to Mid Caps Conference at 8:50 a.m. US EST on Thursday, March 1, 2012. The ASX conference is being held at the Sofitel Hotel in New York.

The information in these presentations has been previously disclosed. Copies of REVA's public presentations, which include recent disclosures, may be accessed under the Investor Relations section of the REVA website at www.revamedical.com.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA's lead product, the ReZolve™ scaffold, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.

The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

CONTACT: United States
         Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         [phone]
         
         Australia
         Investor Enquiries:
         David Allen or Alan Taylor
         Inteq Limited
         [phone]
         
         Media Enquiries:
         Katie Mackenzie or Rebecca Wilson
         Buchan Consulting
         [phone]